The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review

M Pinter, RK Jain, DG Duda - JAMA oncology, 2021 - jamanetwork.com
Importance For more than a decade, sorafenib has been the only systemic treatment option
for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over …
被引用次数：268 相关文章

[引用][C] The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma

M Pinter, RK Jain, DG Duda - JAMA Oncology, 2021 - cir.nii.ac.jp
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.

M Pinter, RK Jain, DG Duda - JAMA Oncology, 2021 - europepmc.org
IMPORTANCE—For more than a decade, sorafenib has been the only systemic treatment
option for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress …

The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review

M Pinter, RK Jain, DG Duda - JAMA oncology, 2021 - pubmed.ncbi.nlm.nih.gov
Importance For more than a decade, sorafenib has been the only systemic treatment option
for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over …
[HTML] nih.gov

[HTML][HTML] The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma A Review

M Pinter, RK Jain, DG Duda - JAMA oncology, 2021 - ncbi.nlm.nih.gov
IMPORTANCE—For more than a decade, sorafenib has been the only systemic treatment
option for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress …